Pharma and biotech companies at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

8 pharma and biotech companies are at ISLB 2026 — 3 presentations on the program. Most represented: AstraZeneca (1 on the program), Menarini Stemline (1 on the program), Pierre Fabre (1 on the program). 2 of them have their own page in this guide. As of Oct 16, 2026.

All 160 organizations at ISLB 2026 →

Showing 1–8 of 8 organizations

Organization	ISLB 2026 Attendance
AstraZeneca Cambridge, United Kingdom	◆Gold Sponsor
astrazeneca.com Large pharmaGold Sponsor Global biopharmaceutical company with oncology among its main therapy areas.	Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Industry Sun Nov 8 8:15am–9:15am Enabling Precision Oncology: The Expanding Role of Liquid Biopsy Across Solid Tumors Clinical use Industry Sun Nov 8 8:15am–9:15am Part of Enabling Precision Oncology: The Expanding Role of Liquid Biopsy Across Solid Tumors Welcome and Introduction Clinical use
Menarini Stemline New York, NY	◆Diamond Sponsor
stemline.com Large pharmaDiamond Sponsor Menarini Group oncology company marketing elacestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.	Industry Sun Nov 8 12:15pm–1:15pm ESR1 Testing in Liquid Biopsy: From Laboratory Excellence to Confident Clinical Decisions Clinical use · Pre-analytics Industry Sun Nov 8 12:15pm–1:15pm Part of ESR1 Testing in Liquid Biopsy: From Laboratory Excellence to Confident Clinical Decisions Clinical Context: When ESR1 Mutation Results as a Predictive Biomarker Drive Treatment Decision, and What the Clinic Needs From the Lab Clinical use · Pre-analytics
Pierre Fabre Castres, France
pierre-fabre.com Large pharma Pharmaceutical and dermo-cosmetics group whose oncology medicines include targeted therapies for melanoma, colorectal and lung cancers.	Poster Part of Poster sessions ctDNA Reveals Early Efficacy Signals and Guides Dose Optimization of PFL-721 in EGFR/HER2 Exon 20 Insertion-Mutant NSCLC: First-in-human Dose-escalation Study Clinical use · ctDNA & MRD
Regeneron Tarrytown, NY	◇Bronze Sponsor
regeneron.com Large pharmaBronze Sponsor Biotechnology drugmaker with marketed antibody medicines, including the cancer immunotherapy cemiplimab and bispecific antibodies for blood cancers.	Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop
Takeda Tokyo, Japan
takeda.com Large pharma Global pharmaceutical company whose oncology medicines cover blood cancers and solid tumours, including lung cancer.	Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop
MSD Rahway, NJ	◆Gold Sponsor
msd.com Large pharmaGold Sponsor Global pharmaceutical company, known as Merck & Co. in the US and Canada, whose oncology medicines include pembrolizumab.	Industry Sat Nov 7 12:30pm–1:30pm Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors Clinical use · ctDNA & MRD
Eli Lilly Indianapolis, IN	◇Bronze Sponsor
lilly.com Large pharmaBronze Sponsor Global pharmaceutical company with cancer medicines for breast, lung and blood cancers.	Sponsor In the meeting’s sponsor directory, with no session on the public program
Johnson & Johnson New Brunswick, NJ	◇Silver Sponsor
jnj.com Large pharmaSilver Sponsor Global healthcare company whose Innovative Medicine unit markets cancer drugs for lung, prostate, bladder cancer and myeloma.	Sponsor In the meeting’s sponsor directory, with no session on the public program